Cargando…
Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe
OBJECTIVE: To assess the effect of route of administration on the bioavailability of dexlansoprazole 60 mg delayed-release capsule granules. METHODS: One open-label, Phase I, single-dose, 3-period crossover study was conducted in healthy adults. The bioavailability of Dexilant(®) (dexlansoprazole) a...
Autores principales: | Kukulka, Michael, Nudurupati, Sai, Perez, Maria Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177519/ https://www.ncbi.nlm.nih.gov/pubmed/30323643 http://dx.doi.org/10.2147/CEG.S138580 |
Ejemplares similares
-
Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
por: Kukulka, Michael, et al.
Publicado: (2016) -
Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration
por: Kukulka, Michael, et al.
Publicado: (2017) -
Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016) -
Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg
por: Kukulka, Michael, et al.
Publicado: (2011) -
Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
por: Kukulka, Michael, et al.
Publicado: (2014)